Amgen Stock Surges on Positive Dazodalibep Trial Results

Amgen stock has drawn attention after its Phase 3 trial win for dazodalibep in moderate-to-severe systemic Sjögren's disease. The company reported positive topline results, with the OASIZ 301 study meeting its primary endpoint by showing a statistically significant and clinically meaningful improvement in ESSDAI at Week 48.

The improvement was seen as early as Week 4 and continued through Week 48, providing a measurable duration signal. This strengthens Amgen's autoimmune pipeline narrative but does not necessarily translate to commercial success, which still depends on detailed efficacy, secondary-endpoint, and regulatory data.

In related news, Amgen reported a 10% rise in Q2 revenue to $10.05 billion, with GAAP diluted EPS reaching $4.37 and non-GAAP diluted EPS at $6.29. The company's market capitalization stands at $225.7 billion, with its stock price currently at $418.13 on Nasdaq.